Eyetech maintained by Merrill at neutral

Eyetech Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Eric Ende at neutral following new data to treat wet age-related macular degeneration for Genentech Inc.'s Lucentis that could impact Eyetech's Macugen sales. Merrill also noted QLT's prostate cancer drug Eligard is facing similar problems. Eyetech shares Tuesday dropped $0.34, or 2.90%, to $11.39 on volume of 6,976,700 shares versus the three-month running average of 4,083,890 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.